# BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

> **NCT02204072** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 120 (actual)

## Conditions studied

- Prostatic Neoplasms, Castration-Resistant

## Interventions

- **DRUG:** BI 836845
- **DRUG:** Enzalutamide
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT02204072
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-11
- **Primary completion:** 2019-10-18
- **Final completion:** 2023-06-01
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02204072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02204072, "BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02204072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*